Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.

Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications. 

Register Now

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

2025 Issues

Molecular pathology selected abstracts

May 2025—As genomic technology and scientific knowledge advance, so too do their applications in health care. Clinical genetic testing, preimplantation genetic diagnosis (PGD), and heritable human genome editing (HHGE) are an ever-growing and evolving part of genomic medicine. The author explored the significance of lived experiences with genetic disease relative to understanding the severity or seriousness of such diseases in the genomic age. She focused on severity of disease, perceptions of symptoms of disease or associations with disease, and interplay between symptoms of disease and associations with disease. The data presented were collected as part of a larger mixed-methods research project exploring factors that influence attitudes toward the use of HHGE as a potential reproductive choice in the United Kingdom and how identifying those factors could aid the design of future regulations.

Q&A column

May 2025
Q. Our laboratory is considering adding whole slide imaging to our surgical pathology case workflow. The quality of the slides can have a negative impact on the scanning of the histologic sections. How can our histology laboratory produce histologic preparations that are optimal for whole slide imaging scanning? Read answer.

Q. Are there biological reference intervals for spot urine values for creatinine, protein, microalbumin, sodium, potassium, and calcium? Some reagent manufacturers give reference intervals for spot urine tests. Is this necessary? Read answer.

Newsbytes

May 2025—Duke University has launched its Duke Center for Computational and Digital Health Innovation, which is intended to drive technological advances in the areas of wearable sensors, high-performance computing, and extended reality solutions. “Our center provides a vibrant platform for innovation and collaboration, where researchers, clinicians, engineers, and industry partners work side-by-side to pioneer new solutions,” says an open letter from Amanda Randles, PhD, director of the center. Faculty support for the center comes from the Duke University School of Medicine, School of Nursing, Trinity College of Arts and Sciences, and Pratt School of Engineering.

Put It on the Board

May 2025—Ninety-nine percent of laboratory professionals say medical couriers impact their work in a “typical week,” with 81 percent of respondents who work in acute care labs indicating the impact is “significant,” according to a CAP TODAY survey sponsored by MedSpeed. Of the 318 laboratory professionals who responded to the 2025 CAP TODAY survey, 84 percent said that in the last month a medical courier delay or error impacted their ability to provide appropriate and timely results for patients, with an average of three such incidents reported per month per respondent. Fifty-six percent of laboratory directors, managers, and supervisors indicated that a courier error compromised an irreplaceable specimen in the last year, with an average of two such incidents reported per respondent per year. And 83 percent of laboratory directors, managers, and supervisors said courier reliability affects their decision to partner with specialty labs or complementary labs for send-out and referral testing.

 

FIGO endometrial cancer staging, 2 years in

April 2025—Seen through the lens of metaphor, cancer staging is traffic control. Identify the biological crash, so to speak, and its severity; direct and redirect therapy; and try, ultimately, to unsnarl persistently risky crossings. That’s the sunny ideal. But efforts to improve traffic flow can also give rise to strong reactions, usually in words (if not a chorus of honking horns). Such is the case with the updated International Federation of Gynecology and Obstetrics staging system for endometrial cancer. FIGO 2023, by nearly all accounts, differs sharply from what had come before, incorporating molecular alterations, lymphovascular invasion, and tumor type and grade. Nearly two years later, it has yet to merge seamlessly into practice. “It definitely is controversial,” says Ekene Okoye, MD, associate professor of clinical pathology and genomic medicine, Department of Pathology and Genomic Medicine, Houston Methodist Hospital and Weill Cornell Medical College.

Not to be overlooked: lab administrative skill

April 2025—The transition from pathology training to practice is not just about diagnostic skill and confidence in that skill but also laboratory administrative duties, with experience in the latter harder to gain as a trainee.

Myeloid malignancies in WHO-HEM5 and ICC

April 2025—Speakers in a CAP24 session last fall spotlighted the differences between the WHO fifth edition of hematolymphoid tumors and the International Consensus Classification and set forth a framework for how to approach myeloid malignancy cases.

More gonorrhea resistance testing needed

April 2025—For Neisseria gonorrhoeae, the pipeline of antibiotics is running dry, and antimicrobial resistance is a global threat. “It’s just a matter of when it’s going to happen,” says Olusegun O. Soge, PhD, MSc, associate professor of global health and of medicine and adjunct associate professor of laboratory medicine and pathology at the University of Washington.

How diagnostics are reshaping the fight against cancer

April 2025—Cancer claims about 10 million lives every year. It is the second leading cause of death in the U.S., according to the American Cancer Society. On World Cancer Day in February, these sobering statistics served as a powerful reminder of the scale of the disease’s impact and how it touches all our lives, directly or indirectly. And with cancer incidence set to rise dramatically, the fight is far from over. The World Health Organization predicts a 60 percent rise in cancer cases globally in the next 20 years, driven by a combination of risk factors. In parallel, health systems are struggling to cope with an aging population, and we see uneven access across the globe to the quality health care that gives the best chance at survival.

At the VHA, a mass-scale move to digital pathology

April 2025—Unprecedented moves with a lot of moving parts is how Jessica Wang-Rodriguez, MD, of the Veterans Health Administration describes a transition to digital pathology the size of the VHA’s. It’s a mission that has become necessary, Dr. Wang-Rodriguez says of the large-scale digital pathology transformation. She is executive director of the VHA National Pathology and Laboratory Medicine Program Office, Washington, DC, and professor of pathology at the University of California, San Diego.

MARKETPLACE

TRENDING